TheraBiogen, Inc. (TRAB) Signs Consulting Agreement With Mr. Dean Blechman, Former Head of Sales at TWINLAB Corp., as Its New Corporate Advisor
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 05/30/12 -- TheraBiogen, Inc. (OTCBB: TRAB), a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today that Dean Blechman, founding family member and former Executive Vice President of Sales at , agreed to become a consultant to the Company and assist the Company primarily in Sales & Marketing. As the former Executive Vice President of Sales at TWINLAB, Mr. Blechman was instrumental in growing TWINLAB's annual revenues from $5 million to over $330 million.
Dean Blechman stated: "I am very excited to be working with TheraBiogen, Inc. to help achieve its anticipated business goals and objectives. I believe the company has great potential and is well-positioned to achieve growth with its line of products. We have agreed that my immediate role will be to ensure that the significant systems and procedures are in place for the organization to run effectively and efficiently."
Additionally, Mr. Blechman may also advise the Company regarding TheraBiogen Inc.'s overall operations with its CEO, Kelly T. Hickel and two new members of its Board of Directors, Mr. Thomas Kelley and Mr. Pat Petruzzo.
Kelly Hickel, CEO of TheraBiogen, stated, "I will voluntarily offer my resignation to the Board of Directors within three months. This decision is best for the Company and the shareholders. I am very enthusiastic working with Dean Blechman during this time."
TheraBiogen's "" product is an all-natural, non-zinc, non-addictive, over-the-counter cold and flu relief agent. Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market according to research studies.
Thera Max® is available for purchase in over twelve thousand locations including , , , Discount Drug Marts and Big Y Supermarkets as well as two of the three largest drug retailers.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market.
Information on Thera Max® can be obtained at , and/or Twitter at .
For information about this release contact Mr. Kelly Hickel at 866-284-9561, and/or Mr. Rich Kaiser, Investor relations, YES INTERNATIONAL, 757-306-6090,
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.
Kelly T. Hickel
CEO
866-284-9561
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.05.2012 - 08:41 Uhr
Sprache: Deutsch
News-ID 1119251
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TheraBiogen, Inc. (TRAB) Signs Consulting Agreement With Mr. Dean Blechman, Former Head of Sales at TWINLAB Corp., as Its New Corporate Advisor
"
steht unter der journalistisch-redaktionellen Verantwortung von
TheraBiogen, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
